Ribavirin antiviral combination therapy in COVID 19, a single-center experience

Budha O Singh, Gaurav Chikara, Prasan Kumar Panda, Yogesh Arvind Bahurupi, Sarama Saha, Venkatesh S. Pai
doi: https://doi.org/10.1101/2022.04.24.22274149

Article Information

doi 
https://doi.org/10.1101/2022.04.24.22274149
History 
  • April 25, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Budha O Singh1,
  2. Gaurav Chikara2,
  3. Prasan Kumar Panda1,*,
  4. Yogesh Arvind Bahurupi3,
  5. Sarama Saha4 and
  6. Venkatesh S. Pai1
  1. 1Department of Internal Medicine (Infectious Disease Division), All India Institute of Medical Sciences (AIIMS), Rishikesh, India
  2. 2Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
  3. 3Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
  4. 4Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
  1. ↵*Corresponding author
    Prasan Kumar Panda, Associate Professor, Dept. of Medicine, Sixth Floor, College Block, All India Institute of Medical Sciences (AIIMS), Rishikesh, India, 249203, Mob: +91-9868999488, motherprasanna{at}rediffmail.com
Back to top
Posted April 25, 2022.
Download PDF
Data/Code
Email
Ribavirin antiviral combination therapy in COVID 19, a single-center experience
Budha O Singh, Gaurav Chikara, Prasan Kumar Panda, Yogesh Arvind Bahurupi, Sarama Saha, Venkatesh S. Pai
medRxiv 2022.04.24.22274149; doi: https://doi.org/10.1101/2022.04.24.22274149
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area